Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316420 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
A Phase 1 study, sponsored by Swedish Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00316420 is a Phase 1 study that has completed, run by Swedish Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT00316420, a Phase 1 study, has completed, sponsored by Swedish Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG Capecitabine (Xeloda)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-12 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316420
The ClinicalTrials.gov registry entry for NCT00316420 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swedish Medical Center, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00316420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00316420 about?
NCT00316420 is a clinical study titled "Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer". The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.
What is the current status of trial NCT00316420?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2003-12. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00316420?
The interventions under investigation include: Gemcitabine (DRUG), Capecitabine (Xeloda) (DRUG).
Who is sponsoring clinical trial NCT00316420?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.